Two Sigma Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Two Sigma Advisers’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89,000	Closed	-$9.55M	–	2748
2023 Q1	$9.55M	Sell	89,000 -46,100	-34%	-$5.31M	0.02%	564
2022 Q4	$14.9M	Buy	135,100 +5,100	+4%	+$331K	0.04%	409
2022 Q3	$7.67M	Buy	130,000 +105,000	+420%	+$4.8M	0.02%	573
2022 Q2	$706K	Buy	+25,000	New	+$725K	﹤0.01%	1769

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Two Sigma Advisers's RXDX Position: Q2 2023 in Review

Two Sigma Advisers sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 89,000 shares — an estimated $9.55M sold.

Two Sigma Advisers first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $14.9M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Two Sigma Advisers reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Two Sigma Advisers sold 89,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $9.55M.
Two Sigma Advisers first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Two Sigma Advisers's Prometheus Biosciences, Inc. Common Stock position peaked at $14.9M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.